PHI 43/24 Issues in July 2024 Prescribed List release

Information about issues in the July 2024 Prescribed List

Date published:
PHI circular type:
Prescribed List announcement
Audience:
Health sector

Following making and publication of the Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 1) 2024 (the Rules) on 22 June 2024, the department has become aware of a small number of issues with the accuracy of the Schedule to the Rules (the July 2024 Prescribed List).

The issues mostly relate to information being inaccurate or omitted/not included in the July 2024 Prescribed List (e.g. incorrect suffixes or benefits; or not listed billing codes). Stakeholders also raised questions about the introduction of a new format for new billing codes.

We are investigating these issues with the view to determining the cause and where required, the action to resolve them.

We ask stakeholders who have identified issues with the billing codes and have not yet raised them with us, to let us know as soon as practicable and no later than Friday 5 July 2024, to prostheses@health.gov.au so that we can take appropriate action.

Other matters

The Therapeutics Goods Administration (TGA) has recently announced the cancellation of several ARTG entries for the spinal cord stimulation devices, with effect mid-July.

Some of these cancelled ARTG entries are recorded for billing codes listed on the Prescribed List. We are considering the appropriate action to be taken in respect to these devices, including removal of billing codes from the PL.

Amending the MDHTP Rules

We anticipate we may need to make an amendment to the Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 1) 2024, which we expect to happen around mid-to-late July 2024.